Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07011797 | A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants | PHASE2 | ACTIVE NOT_RECRUITING | 250 | — | — | Jun 17, 2025 | Apr 6, 2026 | Aug 14, 2025 | 17 | United States |
| Arm | Type | Description |
|---|---|---|
| Placebo group | PLACEBO_COMPARATOR | - |
| 120 mg group | EXPERIMENTAL | - |
| 160 mg group | EXPERIMENTAL | - |
| 200 mg fast titration group | EXPERIMENTAL | - |
| 200 mg slow titration group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CX11 | DRUG | CX11 tablets administered orally once daily (QD) with meals |
| Placebo | OTHER | Matching placebo tablets administered orally once daily (QD) with meals |
Inclusion Criteria Participants who meet all of the following criteria will be eligible to participate in this study: * Between 18 and 75 years old. Both men and women can participate, but women may make up to 70% of the participants. * BMI of 30 or higher, or a BMI between 27 and 30 with at least...